Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C95797
http://purl.obolibrary.org/obo/NCIT_C95797
|
|---|---|
| Preferred Name | Teprotumumab |
| Definitions |
A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Teprotumumab binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Teprotumumab binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. |
|---|---|
| prefLabel | Teprotumumab
|
| label | Teprotumumab
|
| PDQ_Closed_Trial_Search_ID | 557569
|
| code | C95797
|
| Has_Target | |
| prefixIRI | NCIT:C95797
|
| in_subset |
See more
See less
|
| Display_Name | Teprotumumab
|
| Preferred_Name | Teprotumumab
|
| FDA_UNII_Code | Y64GQ0KC0A
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Teprotumumab
|
| CAS_Registry | 89957-37-9
|
| NCI_Drug_Dictionary_ID | 557569
|
| type | |
| ALT_DEFINITION | A human monoclonal antibody being studied in the treatment of several types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. R1507 blocks the action of a protein needed for cell growth and may kill cancer cells. It is a type of insulin-like growth factor-1 receptor (IGF-1R) inhibitor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 557569
|
| Accepted_Therapeutic_Use_For | Treatment of solid and hematologic tumors
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C3181764
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |